Michael Williams, MD
Gastroenterology · Columbia, MONPI 1750334470
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,400 of the $52,406 with a category attached, or 65.6%. Phathom Pharmaceuticals, Inc. accounts for 75.5% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2024 at $40,124 and has fallen 88.6% since, to $4,567 in 2025. Among gastroenterology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 767 payments — averaging $68.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$40K
- AbbVie$3K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Gilead$507
- plus $5K from 32 others
Across 171 payments — averaging $2637.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$216K
- AbbVie$163K
- Braintree Laboratories, Inc.$52K
- Chugai Pharmaceutical Co., Ltd.$15K
- Caris MPI, Inc.$5K
What the payments were for
- Speaking & faculty fees$34,40066%
- Travel & lodging$3,3686%
- Food & beverage$14,53428%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 62 | $39,543 |
| AbbVie(2 entities) | 165 | $3,148 |
| Johnson & Johnson(2 entities) | 97 | $1,653 |
| Takeda Pharmaceuticals U.S.A., Inc. | 81 | $1,364 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 61 | $1,015 |
| Gilead | 36 | $507 |
| Pfizer | 33 | $505 |
| Bristol Myers Squibb | 31 | $498 |
| Amgen | 19 | $390 |
| Nestle Healthcare Nutrition Inc. | 20 | $383 |
| Regeneron Healthcare Solutions, Inc. | 15 | $351 |
| Intercept Pharmaceuticals, Inc. | 20 | $313 |
| Merck | 16 | $287 |
| Aimmune Therapeutics, Inc. | 16 | $275 |
| Celltrion USA Inc. | 12 | $258 |
| Sanofi | 10 | $243 |
| Organon | 9 | $191 |
| Alkermes, Inc. | 8 | $185 |
| Mauna Kea Technologies, Inc. | 6 | $179 |
| Ironwood Pharmaceuticals, Inc | 9 | $158 |
| Lilly USA, LLC | 7 | $136 |
| Kerecis Limited | 1 | $110 |
| Acera Surgical, Inc. | 1 | $90 |
| Medtronic | 1 | $88 |
| Madrigal Pharmaceuticals | 4 | $69 |
| UCB, Inc. | 4 | $62 |
| Novo Nordisk | 2 | $62 |
| Daiichi Sankyo Inc. | 4 | $61 |
| QOL Medical, LLC | 3 | $58 |
| GSK | 3 | $39 |
| Fresenius Kabi USA, LLC | 2 | $37 |
| Zimmer Biomet | 1 | $31 |
| Sandoz | 2 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Dynavax Technologies Corporation | 2 | $23 |
| Exact Sciences | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$38,584
- Kerecis Omega3 Wound$110
How this compares
$52,406 in reported general payments places this provider in the 90th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 37 | $21,310 |
| ViberziEluxadoline | 11 | $17,855 |
| TrulancePlecanatide | 15 | $8,069 |
| Mesalamine | 22 | $6,884 |
| Omeprazole | 405 | $3,344 |
| CholestyramineCholestyramine (With Sugar) | 11 | $3,284 |
| Balsalazide Disodium | 11 | $2,742 |
| Budesonide DrBudesonide | 20 | $1,676 |
| Mesalamine ErMesalamine | 12 | $1,642 |
| Pantoprazole Sodium | 99 | $1,040 |
| Ondansetron Hcl | 16 | $1,013 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 11 | $698 |
| Dicyclomine Hcl | 25 | $644 |
| Sucralfate | 30 | $578 |
| Esomeprazole Magnesium | 29 | $526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Viberzi | $3,148 | $39,16548 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,015 | $8,06915 claims |
| SandozLansoprazole | $27 | $35221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in Columbia
- Bradley AndersonColumbia$194K
- Yezaz GhouriColumbia$32K
- Gregory SayukSaint Louis$1.1M
- Katie SchroederSaint Louis$730K
- David AlpersSaint Louis$616K
- Kamran QureshiLake St Louis$279K
- Laith Al MomaniKansas City$249K
- Ahmed SaeedKansas City$246K
- Parakkal DeepakSaint Louis$205K
- Mauricio Lisker MelmanSaint Louis$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.